Biocon Q1 FY27 Results Analysis: PAT Surges 349%, Finance Costs Decline 23%
Biocon Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 4,336.00 Cr (+10.00% YoY) and PAT growth of +53.40% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 05, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 4,336.00 Cr (+10.00% YoY) |
| PAT (Q1) | Rs. 136.80 Cr (+53.40% YoY) |
| EBITDA margin | 19.54% (+11 bps YoY) |
| EPS (Q1) | Rs. 0.87 (+234.60% YoY) |
| Market cap | Rs. 68,781.18 Cr |
| CMP | Rs. 425.20 |
Quarter Snapshot
Biocon's Q1 FY27 results show strong growth in Biosimilars and Generics, with PAT attributable to owners surging 349% YoY and finance costs declining 23% from debt restructuring. However, the Services segment (Syngene) swung to a loss, dragging overall performance. The H2-weighted trajectory and new product launches provide catalysts, but Syngene's recovery remains the key swing factor.
Key Investment Insights
Key Positives
- Consolidated revenue grew 10.0% YoY to Rs.4,336 Cr
- Biosimilars revenue increased 16.2% YoY to Rs.2,855.6 Cr
- Generics revenue grew 20.5% YoY to Rs.759.7 Cr, with PBIT loss narrowing from -16.12% to -4.07%
- PAT attributable to owners rose 349.4% YoY to Rs.141.1 Cr
- Finance costs fell 23.0% YoY to Rs.213.2 Cr, reflecting debt restructuring benefits
- Standalone PAT turned from a loss of Rs.8.3 Cr to a profit of Rs.52.2 Cr
Risk Factors
- Services/CRDMO revenue declined 15.8% YoY and swung to a PBIT loss of Rs.5.7 Cr from a profit of Rs.101.3 Cr
- Biosimilars PBIT margin eased to 6.00% from 6.78% a year ago, indicating pricing pressure from new product launches and competition
- Generics segment remained loss-making at the PBIT level with a -4.07% margin
- Syngene client concentration risk flagged as a single large molecule biologics client impacted results
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.